
## Eskild Petersen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6603715/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. International Journal of Infectious Diseases, 2022, 114, 268-272.	1.5	136
2	Blue Skies research is essential for ending the Tuberculosis pandemic and advancing a personalized medicine approach for holistic management of Respiratory Tract infections International Journal of Infectious Diseases, 2022, 124, S69-S74.	1.5	3
3	World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic. International Journal of Infectious Diseases, 2022, 124, S1-S3.	1.5	15
4	Optimising tuberculosis care for refugees affected by armed conflicts. Lancet Respiratory Medicine,the, 2022, 10, 533-536.	5.2	3
5	The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to End TB. International Journal of Infectious Diseases, 2022, 124, S26-S29.	1.5	158
6	National case fatality rates of the COVID-19 pandemic. Clinical Microbiology and Infection, 2021, 27, 118-124.	2.8	27
7	COVID-19 in a case previously infected with MERS-CoV: No cross immunity. Journal of Infection, 2021, 82, e28-e29.	1.7	3
8	Accurate Malaria Diagnosis: Not Only Essential for Malaria Case Management, But Prerequisite for Managing Febrile Disease in the Tropics. Clinical Infectious Diseases, 2021, 73, e1168-e1169.	2.9	1
9	One and a half years into the COVID-19 pandemic - exit strategies and efficacy of SARS- CoV-2 vaccines for holistic management and achieving global control. Turkish Journal of Medical Sciences, 2021, 51, 3157-3161.	0.4	6
10	World Tuberculosis Day 2021 Theme — â€~The Clock is Ticking' — and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. International Journal of Infectious Diseases, 2021, 113, S1-S6.	1.5	10
11	COVID-19 vaccines under the International Health Regulations – We must use the WHO International Certificate of Vaccination or Prophylaxis. International Journal of Infectious Diseases, 2021, 104, 175-177.	1.5	21
12	COVID-19 is not influenza. Lancet Respiratory Medicine, the, 2021, 9, 219-220.	5.2	12
13	Answer to Paredes et al. commenting on "COVID-19 vaccines under the International Health Regulations — We must use the WHO International Certificate of Vaccination or Prophylaxis― International Journal of Infectious Diseases, 2021, 105, 409-410.	1.5	0
14	Vaccination against SARS-CoV-2 should be included in childhood vaccination programs. International Journal of Infectious Diseases, 2021, 106, 429-430.	1.5	4
15	Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations. Clinical Microbiology and Infection, 2021, 27, 823-826.	2.8	21
16	COVID-19 health passes: current status and prospects for a global approach. Journal of Travel Medicine, 2021, 28, .	1.4	13
17	COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control. International Journal of Infectious Diseases, 2021, 112, 300-317.	1.5	21
18	Middle East respiratory syndrome coronavirus – The need for global proactive surveillance, sequencing and modeling. Travel Medicine and Infectious Disease, 2021, 43, 102118.	1.5	5

#	Article	IF	CITATIONS
19	Control of the 2018–2019 dengue fever outbreak in Oman: A country previously without local transmission. International Journal of Infectious Diseases, 2020, 90, 97-103.	1.5	18
20	Human Genetics Influence the Susceptibility to Cutaneous Leishmanisis Caused by Leishmania guyanensis. Clinical Infectious Diseases, 2020, 71, 282-283.	2.9	3
21	Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infectious Diseases, The, 2020, 20, e238-e244.	4.6	989
22	Advancing COVID-19 vaccines – avoiding different regulatory standards for different vaccines and need for open and transparent data sharing. International Journal of Infectious Diseases, 2020, 98, 501-502.	1.5	10
23	Lessons from the COVID-19 Pandemic—Unique Opportunities for Unifying, Revamping and Reshaping Epidemic Preparedness of Europe's Public Health Systems. International Journal of Infectious Diseases, 2020, 101, 361-366.	1.5	8
24	The End of the Artemisinin Era—We Should Aim at Malaria Eradication in Asia Using Free, Effective Treatment. Clinical Infectious Diseases, 2020, 73, 414-415.	2.9	0
25	Cost-effectiveness of IGRA/QFT-Plus for TB screening of migrants in Oman. International Journal of Infectious Diseases, 2020, 92, S72-S77.	1.5	14
26	Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak. International Journal of Infectious Diseases, 2020, 93, 205-207.	1.5	49
27	Commemorating World TB Day 2020: "lT'S TIME―— It's time to End the Global TB Epidemic. Interr Journal of Infectious Diseases, 2020, 92, S1-S4.	lational	6
28	Towards identification of novel putative biomarkers for infective endocarditis by serum proteomic analysis. International Journal of Infectious Diseases, 2020, 96, 73-81.	1.5	10
29	Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis — End of the road?. International Journal of Infectious Diseases, 2020, 92, S69-S71.	1.5	12
30	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. International Journal of Infectious Diseases, 2020, 92, S60-S68.	1.5	26
31	The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 2020, 91, 264-266.	1.5	2,658
32	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020, 92, S15-S25.	1.5	126
33	COVID-19–We urgently need to start developing an exit strategy. International Journal of Infectious Diseases, 2020, 96, 233-239.	1.5	67
34	SARS-CoV-2 epidemiology and control, different scenarios for Turkey. Turkish Journal of Medical Sciences, 2020, 50, 509-514.	0.4	16
35	SARS-CoV-2 shedding and infectivity. Lancet, The, 2020, 395, 1339-1340.	6.3	125
36	COVID-19 travel restrictions and the International Health Regulations – Call for an open debate on easing of travel restrictions. International Journal of Infectious Diseases, 2020, 94, 88-90.	1.5	27

#	Article	IF	CITATIONS
37	High-income countries and latent tuberculosis infection screening for migrants – Authors' reply. Lancet Infectious Diseases, The, 2019, 19, 691-692.	4.6	2
38	Inhaled nebulized glatiramer acetate against Gram-negative bacteria is not associated with adverse pulmonary reactions in healthy, young adult female pigs. PLoS ONE, 2019, 14, e0223647.	1.1	5
39	Human Monkeypox. Infectious Disease Clinics of North America, 2019, 33, 1027-1043.	1.9	432
40	Severe imported malaria in an intensive care unit: A case series. IDCases, 2019, 17, e00544.	0.4	5
41	Latent tuberculosis infection: diagnostic tests and when to treat. Lancet Infectious Diseases, The, 2019, 19, 231-233.	4.6	15
42	World Tuberculosis Day March 24th 2019 Theme: "lt's TIME―— International Journal of Infectious Diseases Tuberculosis Theme Series. International Journal of Infectious Diseases, 2019, 80, S1-S5.	1.5	3
43	Latent toxoplasmosis aggravates anxiety- and depressive-like behaviour and suggest a role of gene-environment interactions in the behavioural response to the parasite. Behavioural Brain Research, 2019, 364, 133-139.	1.2	27
44	Molecular characterization of human enteric viruses in food, water samples, and surface swabs in Sicily. International Journal of Infectious Diseases, 2019, 80, 66-72.	1.5	54
45	Monkeypox — Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. International Journal of Infectious Diseases, 2019, 78, 78-84.	1.5	133
46	Should travellers be offered vaccination against the dengue virus?. Travel Medicine and Infectious Disease, 2019, 27, 2-4.	1.5	1
47	Title is missing!. , 2019, 14, e0223647.		0
48	Title is missing!. , 2019, 14, e0223647.		0
49	Title is missing!. , 2019, 14, e0223647.		Ο
50	Title is missing!. , 2019, 14, e0223647.		0
51	Malaria Disease Recommendations for Solid Organ Transplant Recipients and Donors. Transplantation, 2018, 102, S16-S26.	0.5	30
52	Detection of the Malaria causing Plasmodium Parasite in Saliva from Infected Patients using Topoisomerase I Activity as a Biomarker. Scientific Reports, 2018, 8, 4122.	1.6	20
53	Global spread of antibiotic-resistant bacteria and mass-gathering religious events. Lancet Infectious Diseases, The, 2018, 18, 488-490.	4.6	9
54	Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors. Transplantation, 2018, 102, 193-208.	0.5	53

#	Article	IF	CITATIONS
55	Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 — "Wanted: Leaders for a TB-Free World. You can make history. End TB― International Journal of Infectious Diseases, 2018, 68, 122-124.	1.5	9
56	Double Infection With Leishmania tropica and L. major in an HIV Patient Controlled With High Doses of Amphotericin B. Open Forum Infectious Diseases, 2018, 5, ofy323.	0.4	7
57	Overcoming â€~purview paradox' to make way for the effective implementation of PrEP in preventing HIV transmission. International Journal of Infectious Diseases, 2018, 77, 105-106.	1.5	9
58	The historic and unprecedented United Nations General Assembly High Level Meeting on Tuberculosis (UNGA-HLM-TB)—â€~United to End TB: An Urgent Global Response to a Global Epidemic'. International Journal of Infectious Diseases, 2018, 75, 118-120.	1.5	24
59	Late onset acute pancreatitis in P. falciparum malaria – An adverse reaction to intravenous artesunate?. IDCases, 2018, 12, 124-126.	0.4	6
60	Ultra-dense polymer brush coating reduces Staphylococcus epidermidis biofilms on medical implants and improves antibiotic treatment outcome. Acta Biomaterialia, 2018, 76, 46-55.	4.1	29
61	Football fever in Russia: Infectious disease risks and the FIFA world cup 2018. Travel Medicine and Infectious Disease, 2018, 24, 4-6.	1.5	4
62	World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB―Era. International Journal of Infectious Diseases, 2017, 56, 1-5.	1.5	19
63	De-isolation of patients with pulmonary tuberculosis after start of treatment — clear, unequivocal guidelines are missing. International Journal of Infectious Diseases, 2017, 56, 34-38.	1.5	13
64	Current status of Crimean-Congo haemorrhagic fever in the World Health Organization Eastern Mediterranean Region: issues, challenges, and future directions. International Journal of Infectious Diseases, 2017, 58, 82-89.	1.5	128
65	Imported Talaromycosis in Oman in Advanced HIV: A Diagnostic Challenge Outside the Endemic Areas. Mycopathologia, 2017, 182, 739-745.	1.3	11
66	Travellers' Malaria - Horizons 202X. Travel Medicine and Infectious Disease, 2017, 17, 1-2.	1.5	2
67	An outbreak of locally acquired Plasmodium vivax malaria among migrant workers in Oman. Parasite, 2017, 24, 25.	0.8	11
68	The challenges of cholera at the 2017 Hajj pilgrimage. Lancet Infectious Diseases, The, 2017, 17, 895-897.	4.6	10
69	Ending the Global Tuberculosis Epidemic by 2030 — The Moscow Declaration and achieving a Major Translational Change in Delivery of TB Healthcare. International Journal of Infectious Diseases, 2017, 65, 156-158.	1.5	14
70	The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria. Scientific Reports, 2017, 7, 15653.	1.6	25
71	Anemia and growth retardation associated with Schistosoma haematobium infection in Mali: a possible subtle impact of a neglected tropical disease. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 144-153.	0.7	13
72	Genetic diversity of Plasmodium vivax metacaspase 1 and Plasmodium vivax multi-drug resistance 1 genes of field isolates from Mauritania, Sudan and Oman. Malaria Journal, 2017, 16, 61.	0.8	5

#	Article	IF	CITATIONS
73	Impact of infectious disease epidemics on tuberculosis diagnostic, management, and prevention services: experiences and lessons from the 2014–2015 Ebola virus disease outbreak in West Africa. International Journal of Infectious Diseases, 2017, 56, 101-104.	1.5	38
74	Health systems in the Republic of Congo: challenges and opportunities for implementing tuberculosis and HIV collaborative service, research, and training activities. International Journal of Infectious Diseases, 2017, 56, 62-67.	1.5	11
75	Penicillin G Treatment in Infective Endocarditis Patients – Does Standard Dosing Result in Therapeutic Plasma Concentrations?. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 179-186.	1.2	5
76	Organomegaly in Mali before and after praziquantel treatment. A possible association with Schistosoma haematobium. Heliyon, 2017, 3, e00440.	1.4	0
77	Hyperbaric Oxygen Therapy is Ineffective as an Adjuvant to Daptomycin with Rifampicin Treatment in a Murine Model of Staphylococcus aureus in Implant-Associated Osteomyelitis. Microorganisms, 2017, 5, 21.	1.6	12
78	One-sixth of inpatients in a Danish infectious disease ward have imported diseases: A cross-sectional analysis. Travel Medicine and Infectious Disease, 2017, 20, 43-48.	1.5	4
79	Drug resistant pathogens and travel: No road map but a new initiative from Travel Medicine and Infectious Disease. Travel Medicine and Infectious Disease, 2016, 14, 543-545.	1.5	1
80	Should travelers be screened for multi-drug resistant (MDR) bacteria after visiting high risk areas such as India?. Travel Medicine and Infectious Disease, 2016, 14, 591-594.	1.5	4
81	Reducing risks to health and wellbeing at mass gatherings: the role of the Sendai Framework for Disaster Risk Reduction. International Journal of Infectious Diseases, 2016, 47, 101-104.	1.5	34
82	Active screening and surveillance in the United Kingdom for Middle East respiratory syndrome coronavirus in returning travellers and pilgrims from the Middle East: a prospective descriptive study for the period 2013–2015. International Journal of Infectious Diseases, 2016, 47, 10-14.	1.5	38
83	Rifampicin-containing combinations are superior to combinations of vancomycin, linezolid and daptomycin against <i>Staphylococcus aureus</i> biofilm infection <i>in vivo</i> and <i>in vitro</i> . Pathogens and Disease, 2016, 74, ftw019.	0.8	41
84	Crimean-Congo hemorrhagic fever – A ticking bomb?. Travel Medicine and Infectious Disease, 2016, 14, 71-72.	1.5	1
85	To have sepsis or to be septic—is the difference between these clinical conditions important?. International Journal of Infectious Diseases, 2016, 48, 118-119.	1.5	5
86	Piperacillin/tazobactam continuous infusion at 12G/1.5G per day in CF patients results in target plasma-concentrations. Journal of Cystic Fibrosis, 2016, 15, e13-e14.	0.3	3
87	Hosting of mass gathering sporting events during the 2013–2016 Ebola virus outbreak in West Africa: experience from three African countries. International Journal of Infectious Diseases, 2016, 47, 38-41.	1.5	17
88	The annual Hajj pilgrimage—minimizing the risk of ill health in pilgrims from Europe and opportunity for driving the best prevention and health promotion guidelines. International Journal of Infectious Diseases, 2016, 47, 79-82.	1.5	40
89	Artemether–Lumefantrine Concentrations in Tablets and Powders from Ghana Measured by a New High-Performance Liquid Chromatography Method. American Journal of Tropical Medicine and Hygiene, 2016, 95, 158-163.	0.6	5
90	Taking forward a â€~One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential. International Journal of Infectious Diseases, 2016, 47, 5-9.	1.5	81

#	Article	IF	CITATIONS
91	Tuberculosis and mass gatherings—opportunities for defining burden, transmission risk, and the optimal surveillance, prevention, and control measures at the annual Hajj pilgrimage. International Journal of Infectious Diseases, 2016, 47, 86-91.	1.5	25
92	In silico and in vivo analysis of Toxoplasma gondii epitopes by correlating survival data with peptide–MHC-I binding affinities. International Journal of Infectious Diseases, 2016, 48, 14-19.	1.5	6
93	Comparison of sensitivity and specificity of 4 methods for detection of Giardia duodenalis in feces: immunofluorescence and PCR are superior to microscopy of concentrated iodine-stained samples. Diagnostic Microbiology and Infectious Disease, 2016, 84, 187-190.	0.8	31
94	Rapid Spread of Zika Virus in The Americas - Implications for Public Health Preparedness for Mass Gatherings at the 2016 Brazil Olympic Games. International Journal of Infectious Diseases, 2016, 44, 11-15.	1.5	306
95	Taking forward the World TB Day 2016 theme â€~Unite to End Tuberculosis' for the WHO Africa Region. International Journal of Infectious Diseases, 2016, 46, 34-37.	1.5	14
96	Zika virus outbreak and the case for building effective and sustainable rapid diagnostics laboratory capacity globally. International Journal of Infectious Diseases, 2016, 45, 92-94.	1.5	19
97	Co-administration of interleukins 7 and 15 with DNA vaccine improves protective immunity against Toxoplasma gondii. Experimental Parasitology, 2016, 162, 18-23.	0.5	20
98	A systematic review of biomarkers in the diagnosis of infective endocarditis. International Journal of Cardiology, 2016, 202, 564-570.	0.8	27
99	Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV. BMC Immunology, 2015, 16, 65.	0.9	15
100	Commemorating World Tuberculosis Day 2015. International Journal of Infectious Diseases, 2015, 32, 1-4.	1.5	2
101	Tackling the Tuberculosis Epidemic in sub-Saharan Africa – unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024. International Journal of Infectious Diseases, 2015, 32, 46-49.	1.5	49
102	Advancing the global health security agenda in light of the 2015 annual Hajj pilgrimage and other mass gatherings. International Journal of Infectious Diseases, 2015, 40, 133-134.	1.5	5
103	Middle East Respiratory Syndrome– advancing the public health and research agenda on MERS- lessons from the South Korea outbreak. International Journal of Infectious Diseases, 2015, 36, 54-55.	1.5	50
104	Acute and long-term psychiatric side effects of mefloquine: A follow-up on Danish adverse event reports. Travel Medicine and Infectious Disease, 2015, 13, 80-88.	1.5	35
105	Periorbital Dirofilaria repens imported to Denmark: A human case report. IDCases, 2015, 2, 25-26.	0.4	19
106	Moxifloxacin Pharmacokinetic Profile and Efficacy Evaluation in Empiric Treatment of Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2015, 59, 2398-2404.	1.4	14
107	Should We Offer Screening for Hepatitis B and Other Infections to Immigrants—Legal or Illegal?. Journal of Travel Medicine, 2015, 22, 73-75.	1.4	1
108	The era of antibiotic-resistant bacteria – Time for political, travel medicine and healthcare decisions. Travel Medicine and Infectious Disease, 2015, 13, 279-280.	1.5	3

#	Article	IF	CITATIONS
109	Recent advances in developing vaccines against <i>Toxoplasma gondii</i> : an update. Expert Review of Vaccines, 2015, 14, 1609-1621.	2.0	90
110	Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis. BMC Infectious Diseases, 2015, 15, 290.	1.3	8
111	Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. International Journal of Infectious Diseases, 2015, 40, 71-74.	1.5	38
112	Considering treatment of male genital schistosomiasis as a tool for future HIV prevention: a systematic review. International Journal of Public Health, 2015, 60, 839-848.	1.0	21
113	Middle East Respiratory Syndrome - need for increased vigilance and watchful surveillance for MERS-CoV in sub-Saharan Africa. International Journal of Infectious Diseases, 2015, 37, 77-79.	1.5	15
114	Reflections on travel-associated infections in Europe. Lancet Infectious Diseases, The, 2015, 15, 6-8.	4.6	4
115	Guidelines for treatment of patients with Ebola Virus Diseases are urgently needed. International Journal of Infectious Diseases, 2015, 30, 85-86.	1.5	5
116	A Modified Chronic Infection Model for Testing Treatment of Staphylococcus aureus Biofilms on Implants. PLoS ONE, 2014, 9, e103688.	1.1	30
117	Reply to Shin and Bayry on "An age-related decline of CD62L and vaccine response: a role of microRNA 92a?― Human Vaccines and Immunotherapeutics, 2014, 10, 1406-1407.	1.4	Ο
118	Health-care associate transmission of Middle East Respiratory Syndrome Corona virus, MERS-CoV, in the Kingdom of Saudi Arabia. International Journal of Infectious Diseases, 2014, 29, 299-300.	1.5	14
119	Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice. Vaccine, 2014, 32, 3058-3065.	1.7	41
120	Middle East Respiratory Syndrome Corona virus, MERS-CoV. Conclusions from the 2nd Scientific Advisory Board Meeting of the WHO Collaborating Center for Mass Gathering Medicine, Riyadh. International Journal of Infectious Diseases, 2014, 24, 51-53.	1.5	21
121	Vertebral infection with Candida albicans failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine. Medical Mycology Case Reports, 2014, 6, 6-9.	0.7	10
122	Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women. International Journal of Infectious Diseases, 2014, 28, 41-44.	1.5	13
123	Tools for travellers' diarrhoea: Bring back the vaccine?. Travel Medicine and Infectious Disease, 2014, 12, 305-306.	1.5	2
124	Toxoplasma gondii: Protective immunity induced by rhoptry protein 9 (TgROP9) against acute toxoplasmosis. Experimental Parasitology, 2014, 139, 42-48.	0.5	27
125	Plasmodium vivax malaria: A re-emerging threat for temperate climate zones?. Travel Medicine and Infectious Disease, 2013, 11, 51-59.	1.5	26
126	Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?. Molecular and Cellular Therapies, 2013, 1, 2.	0.2	12

#	Article	IF	CITATIONS
127	Epidemiology of Ocular Toxoplasmosis. Ocular Immunology and Inflammation, 2012, 20, 68-75.	1.0	84
128	Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scandinavian Journal of Infectious Diseases, 2011, 43, 495-503.	1.5	34
129	The Protease Inhibitors Ritonavir and Saquinavir Influence Lipid Metabolism: A Pig Model for the Rapid Evaluation of New Drugs. Antiviral Therapy, 2010, 15, 243-251.	0.6	0
130	Procalcitonin in 759 Patients Clinically Suspected of Infective Endocarditis. American Journal of Medicine, 2010, 123, 1121-1127.	0.6	20
131	Infective endocarditis: a continuous challenge. The recent experience of a European tertiary center. Journal of Heart Valve Disease, 2009, 18, 386-94.	0.5	9
132	Population-based study of diagnostic assays for Borrelia infection: comparison of purified flagella antigen assay (Ideiaâ,,¢, Dako Cytomation) and recombinant antigen assay (Liaison®, DiaSorin). BMC Clinical Pathology, 2008, 8, 4.	1.8	5
133	Protozoan and helminth infections in pregnancy. Short-term and long-term implications of transmission of infection from mother to foetus. Parasitology, 2007, 134, 1855-1862.	0.7	13
134	Prevention and treatment of congenital toxoplasmosis. Expert Review of Anti-Infective Therapy, 2007, 5, 285-293.	2.0	33
135	Toxoplasmosis. Seminars in Fetal and Neonatal Medicine, 2007, 12, 214-223.	1.1	143
136	Malaria chemoprophylaxis: when should we use it and what are the options?. Expert Review of Anti-Infective Therapy, 2004, 2, 119-132.	2.0	33